All In Biotech

Drug Trial Radar · NCT03722329

Pharmacokinetic, Safety, Tolerability, Immunogenicity, and Pharmacodynamic Study of SB12 in Healthy Subjects

A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, Immunogenicity, and Pharmacodynamics of Eculizumab (SB12, EU Sourced Soliris®, and US Sourced Soliris®) in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Jan 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

Nov 13, 2018

Primary completion

Mar 29, 2019

Study completion Apr 8, 2019

Sponsor

Lead sponsor
Samsung Bioepis Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is to evaluate PK, safety, tolerability, immunogenicity, and PD profiles of SB12, EU sourced Soliris, and US sourced Soliris in healthy subjects.

Conditions

  • Healthy

Interventions

  • EculizumabDrug

    Eculizumab Injection. 300 mg, single dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCinfTime frame: Day 1 to Day 64

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PAREXEL International GmbH, Early Phase Clinical Unit - Berlin

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.